Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

Bookmark and Share
Published: 7 Dec 2017
Views: 1498
Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Loi speaks at a SABCS 2017 press session about data presented from the phase Ib/II PANACEA trial.

She describes how a combination of pembrolizumab and trastuzumab, tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab.

Read the news story for more.